Efficacy and safety of remimazolam versus dexmedetomidine for patients undergoing flexible fiberoptic bronchoscopy: A randomized, clinical trial
Authors' conclusion
Remimazolam is effective and safe in painless flexible fiberoptic bronchoscopy. It allows a lower procedure interruption rate and incidence of oxygen desaturation, providing better hemodynamic stability compared to dexmedetomidine.
Study context
- Population
- Patients undergoing painless flexible fiberoptic bronchoscopy, university hospital, April 2021–September 2022included for final analysis
- Participants
- 363 patients
- Comparison
- Remimazolam-remifentanil vs dexmedetomidine-remifentanil
- Primary endpoint
- Procedure interruption rate during bronchoscopy
Methodological details1:1 randomisation
- 1:1 randomisation
Primary result
As reported in the abstract
P < 0.05
Secondary outcomes
Rescue medication usage rate
P < 0.05
Rescue medication dose
P < 0.05
Hemodynamic changes, recovery time, patient and bronchoscopist satisfaction
- Significant hemodynamic changes, longer recovery time and lower satisfaction scores in DR vs RR (P < 0.05)
Safety
Oxygen desaturation
P < 0.05
Operation-related complications
- No significant differences between groups (P > 0.05) except postoperative dizziness, more common in DR (P < 0.05)
Original publication
Efficacy and safety of remimazolam versus dexmedetomidine for patients undergoing flexible fiberoptic bronchoscopy: A randomized, clinical trial. J Clin Anesth. Published 7 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →